|
AU2007237096C1
(en)
|
2006-04-07 |
2012-12-13 |
EyePoint, Inc. |
Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
|
|
AU2012323856B2
(en)
|
2011-10-13 |
2017-05-25 |
EyePoint, Inc. |
Methods for treating Vascular Leak Syndrome and cancer
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
CA2990885A1
(en)
|
2015-06-30 |
2017-01-05 |
Sanford-Burnham Medical Research Institute |
Btla fusion protein agonists and uses thereof
|
|
KR102799807B1
(ko)
|
2015-12-30 |
2025-04-24 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
KR102726248B1
(ko)
|
2016-07-07 |
2024-11-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
항체-애쥬번트 접합체
|
|
EP3630179A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
|
SMT202300418T1
(it)
|
2017-05-30 |
2024-01-10 |
Bristol Myers Squibb Co |
Trattamento di tumori positivi per lag-3
|
|
MX2020009152A
(es)
|
2018-03-02 |
2020-11-09 |
Kodiak Sciences Inc |
Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
|
|
CN120058958A
(zh)
|
2018-09-24 |
2025-05-30 |
视点制药公司 |
靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
|
|
CA3125748A1
(en)
*
|
2019-01-07 |
2020-07-16 |
Thomas Jefferson University |
Multi-functional fusion proteins and uses thereof
|
|
AU2020241686A1
(en)
|
2019-03-15 |
2021-11-04 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting HER2
|
|
WO2020234834A1
(en)
|
2019-05-23 |
2020-11-26 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
CA3135988C
(en)
|
2019-06-10 |
2024-11-19 |
Shandong Boan Biotechnology Co., Ltd. |
Bifunctional fusion protein against PD-L1 and TGFS and its use
|
|
CN114728040A
(zh)
*
|
2019-06-14 |
2022-07-08 |
科优基因公司 |
新型白介素-2变体及其双功能融合分子
|
|
WO2020257196A1
(en)
*
|
2019-06-17 |
2020-12-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating infections by blocking pathogen mimics of cd47
|
|
WO2021007428A2
(en)
*
|
2019-07-09 |
2021-01-14 |
The Johns Hopkins University |
Molecules, compositions and methods for treatment of cancer
|
|
CN110627905B
(zh)
*
|
2019-09-18 |
2021-04-27 |
中国医学科学院肿瘤医院 |
靶向vegf与egfr的双功能融合蛋白及其应用
|
|
CA3153777A1
(en)
*
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
CN112574314A
(zh)
*
|
2019-09-30 |
2021-03-30 |
和铂医药(苏州)有限公司 |
一种融合蛋白及其应用
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
BR112022008191A2
(pt)
*
|
2019-11-08 |
2022-07-12 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para melanoma
|
|
AU2020402496A1
(en)
*
|
2019-12-11 |
2022-06-16 |
WuXi Biologics Ireland Limited |
Bi-functional antibody against PD-L1 and TGFβ
|
|
JP7730817B6
(ja)
*
|
2019-12-20 |
2025-09-26 |
アレス トレーディング ソシエテ アノニム |
ＩｇＧ：ＴＧＦβＲＩＩ融合タンパク質組成物
|
|
US11045546B1
(en)
|
2020-03-30 |
2021-06-29 |
Cytodyn Inc. |
Methods of treating coronavirus infection
|
|
US20230235057A1
(en)
*
|
2020-04-29 |
2023-07-27 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Bifunctional protein against pd-1 and tgf-beta
|
|
EP4146273A4
(en)
*
|
2020-05-05 |
2024-07-31 |
Janssen Biotech, Inc. |
METHODS OF TREATING CROHN'S DISEASE USING A SPECIFIC ANTI-IL23 ANTIBODY
|
|
WO2021231773A1
(en)
|
2020-05-13 |
2021-11-18 |
Good Therapeutics, Inc. |
Compositions of protein complexes and methods of use thereof
|
|
KR20230023663A
(ko)
|
2020-05-21 |
2023-02-17 |
얀센 바이오테크 인코포레이티드 |
Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
|
|
MX2023000005A
(es)
*
|
2020-06-26 |
2023-03-06 |
Sorrento Therapeutics Inc |
Virus del herpes simple (vhs) oncolíticos que expresan proteínas de fusión inmunomoduladoras.
|
|
EP4178616A4
(en)
*
|
2020-07-13 |
2024-07-24 |
Janssen Biotech, Inc. |
SAFE AND EFFECTIVE METHOD FOR TREATING PSORIATIC ARTHRITIS USING A SPECIFIC ANTI-IL23 ANTIBODY
|
|
CN116261448A
(zh)
*
|
2020-08-19 |
2023-06-13 |
百奥泰生物制药股份有限公司 |
用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂
|
|
WO2022087402A1
(en)
|
2020-10-23 |
2022-04-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
CN114539415B
(zh)
*
|
2020-11-24 |
2024-02-02 |
普米斯生物技术(珠海)有限公司 |
一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
|
|
US20230416394A1
(en)
*
|
2020-11-27 |
2023-12-28 |
Elpiscience (Suzhou) Biopharma, Ltd. |
Novel conjugate molecules targeting cd39 and tgfbeta
|
|
CA3211803A1
(en)
*
|
2021-02-27 |
2022-09-01 |
Eluminex Biosciences (Suzhou) Limited |
Antibody fusion proteins targeting il-6 receptor and angiogenic factors
|
|
BR112023018400A2
(pt)
*
|
2021-03-12 |
2023-12-12 |
Janssen Biotech Inc |
Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
|
|
MX2023010705A
(es)
*
|
2021-03-12 |
2023-11-22 |
Janssen Biotech Inc |
Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
|
|
CN113698493B
(zh)
*
|
2021-08-09 |
2022-05-31 |
北京东方百泰生物科技股份有限公司 |
一种针对VEGF和TGF-β的双功能蛋白及其应用
|
|
EP4434548A1
(en)
|
2021-11-15 |
2024-09-25 |
Systimmune, Inc. |
Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
|
|
WO2023146654A1
(en)
*
|
2022-01-31 |
2023-08-03 |
Fbd Biologics Limited |
Engineered pd-1 variants and methods of use thereof
|
|
EP4249510A1
(en)
*
|
2022-03-22 |
2023-09-27 |
Stealth IO |
Novel formats of anti-cd28/spd-1 fusion constructs
|
|
CN117624375A
(zh)
*
|
2022-08-30 |
2024-03-01 |
北京卡替医疗技术有限公司 |
增强受体、表达增强受体的免疫细胞及其用途
|
|
CN116554300B
(zh)
*
|
2023-04-27 |
2023-10-24 |
湖北医药学院 |
一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用
|